# Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure

Study · id `cardio:ct-nct06669169` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06669169](<https://clinicaltrials.gov/study/NCT06669169>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06669169

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 288 participants.

## Technical summary

Registry record NCT06669169. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-31 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 288 participants (planned count; ClinicalTrials.gov record NCT06669169, source copy `cardio:ctgov-nct06669169-2024-11-01`, retrieved 2026-10-26)
- Planned start: 2025-01-31 (anticipated) (ClinicalTrials.gov record NCT06669169, source copy `cardio:ctgov-nct06669169-2024-11-01`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06669169, source copy `cardio:ctgov-nct06669169-2024-11-01`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06669169, source copy `cardio:ctgov-nct06669169-2024-11-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06669169, source copy `cardio:ctgov-nct06669169-2024-11-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06669169-2024-11-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
- Condition: Heart Failure
- Intervention (Drug): Jia Shen Tablet Placebo
- Intervention (Drug): Low dose Jia Shen Tablet
- Intervention (Drug): High dose Jia Shen Tablet
- Lead sponsor: Tasly Pharmaceutical Group Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Tasly Pharmaceutical Group Co., Ltd (`cardio:org-tasly-pharmaceutical-group-co-ltd`)

## Provenance

Content hash: 78ca290801ce01a0678e8fce1c20132777f5d6da8ec01f3cba44ce3da5952d9a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
